References
1. Souissi A, Dergaa I, Romdhani M, Ghram A, Irandoust K, Chamari K, et
al. Can melatonin reduce the severity of post-COVID-19 syndrome? EXCLI
journal. 2023;22:173.2. Semenzato L, Le Vu S, Botton J, Bertrand M,
Jabagi M-J, Drouin J, et al. Long-Term Prognosis of Patients With
Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2
Infection, or Conventional Etiologies. JAMA. 2024;332(16):1367-77.3.
Ammirati E, Moslehi JJ. Diagnosis and Treatment of Acute Myocarditis: A
Review. JAMA. 2023;329(13):1098-113.4. Sterne JA, Murthy S, Diaz JV,
Slutsky AS, Villar J, Angus DC, et al. Association between
administration of systemic corticosteroids and mortality among
critically ill patients with COVID-19: a meta-analysis. Jama.
2020;324(13):1330-41.5. Cutolo M. Glucocorticoids and chronotherapy in
rheumatoid arthritis. RMD open. 2016;2(1):e000203.6. Arendt J. Does
melatonin improve sleep? Efficacy of melatonin. BMJ: British Medical
Journal. 2006;332(7540):550.7. Bantounou M, Plascevic J, Galley HF.
Melatonin and related compounds: antioxidant and anti-inflammatory
actions. MDPI; 2022. p. 532.8. Wang J, Gao S, Lenahan C, Gu Y, Wang X,
Fang Y, et al. Melatonin as an antioxidant agent in stroke: An updated
review. Aging and disease. 2022;13(6):1823.9. Dominguez-Rodriguez A,
Abreu-Gonzalez P, Reiter RJ. Melatonin for cardioprotection in ST
elevation myocardial infarction: are we ready for the challenge? : BMJ
Publishing Group Ltd and British Cardiovascular Society; 2017. p.
647-8.10. Zisapel N, Tarrasch R, Laudon M. The relationship between
melatonin and cortisol rhythms: clinical implications of melatonin
therapy. Drug development research. 2005;65(3):119-25.